Codexis (NASDAQ:CDXS – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Benchmark in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $9.00 target price on the biotechnology company’s stock. Benchmark’s target price suggests a potential upside of 129.59% from the stock’s current […]